Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 studyCéline Berthon, Hervé Dombret, Carmen Kahatt et al.|The Lancet Haematology|2016Cited by 431
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AMLJad Othman, Richard Dillon, Nicola Potter et al.|Leukemia|2023Cited by 48
Venetoclax–based low intensity therapy in molecular failure of <i>NPM1</i>-mutated AMLCarlos Jiménez‐Chillón, Richard Dillon, Jad Othman et al.|Blood Advances|2023Cited by 29
A global study for acute myeloid leukemia with <i>RARG</i> rearrangementHong‐Hu Zhu, Suning Chen, Ya‐Zhen Qin et al.|Blood Advances|2023Cited by 26
Outcomes with single-agent gilteritinib for relapsed or refractory <i>FLT3</i>-mutant AML after contemporary induction therapyJad Othman, Richard Dillon, Angela Hwang et al.|Blood Advances|2024Cited by 10